欢迎访问《标记免疫分析与临床》官方网站!
综述

放射性核素131I在甲亢治疗中的应用现状和进展

展开
  • (北京大学第一医院核医学科,北京 100034)
吴茜(1990-),女,临床医学专业8年制博士研究生,研究方向:临床核医学。 E-mail: pkuwuqian@gmail.com

收稿日期: 2014-05-23

  修回日期: 2014-11-04

  网络出版日期: 2015-01-25

基金资助

国家自然科学基金(81071183);国家重大科学仪器设备开发专项(2011YQ03011409);十二五国家支撑项目基金(2014BAA03B03)

Overview and Progress of 131I in the Treatment of Hyperthyroidism

Expand
  • Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China

Received date: 2014-05-23

  Revised date: 2014-11-04

  Online published: 2015-01-25

摘要

以Graves病为代表,探讨放射性核素131I在甲亢治疗学中的应用,归纳、总结和讨论131I在甲亢治疗中的适应症、剂量、联合治疗、疗效和转归。与传统治疗方法相比,131I治疗甲亢具有快速简便、不良反应少、治疗效果好、费用低等优点,逐渐成为甲亢治疗的主流方法,但治疗时需注意向甲减的转归

本文引用格式

吴 茜,王荣福 . 放射性核素131I在甲亢治疗中的应用现状和进展[J]. 标记免疫分析与临床, 2015 , 22(1) : 66 . DOI: 10.11748/bjmy.issn.1006-1703.2015.01.021

Abstract

In view of Graves disease as a representative of hyperthyroidism,we discuss the application of radionuclide 131I in the treatment of hyperthyroidism. The indications, dose selection, combined treatment, efficacy and hypothyroidism in 131I therapy were summarized. Compared with the traditional treatment methods, 131I therapy for hyperthyroidism has advantages of fast, easy, less adverse reactions, high efficiency and low cost, and it gradually becomes the mainstream method of treatment of hyperthyroidism, but the treatment of hypothyroidism outcome should be paid more attention.
文章导航

/